ProMIS Neurosciences, Inc.

NASDAQ:PMN

Biotechnology

Healthcare
$11.08 -0.14%

-$0.02 today

Market cap
$99.36M
Beta
-0.22
P/E (TTM)
-0.6
EPS (TTM)
-$4.62
52W Low $6.27High $27.40

Volume 0.13M

Average 0.07M

PMN Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

ProMIS Neurosciences, Inc.NASDAQ: PMN

Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026

Accumulated OCI remains negative

Q2 FY2026 Accumulated OCI was -$371.18K, compared with -$371.18K a year earlier.

Context

  • Accumulated OCI amounted to 0.7% of total assets at the end of Q2 FY2026, down 3.2 pp from a year earlier.
  • Accumulated OCI grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$371.18K+0.0% QoQ
Last fiscal yearDec 2025
-$371.18K+0.0% YoY
Year agoJun 2025
-$371.18K+0.0% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

Mixed currencies · from the balance sheet

Latest · FY2025
(371.18K) USD
Year-over-year change
+0.0%

Accumulated OCI vs competitors

How PMN compares with its peers on the latest reported figures

  • PMN's Jun 2026 Accumulated OCI of -$371.18K is the 2nd highest of the 4 companies compared; the peer median is -$883K.
  • Its year-over-year change of +0.0% is the 3rd highest of 4, against a peer median of +4.2%.
  • Accumulated OCI amounts to 0.7% of total assets for PMN, versus a peer median of 1.5%.
PMN Competitors Peer median
Accumulated OCI for PMN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EDSAEdesa Biotech, Inc.Mar 2026-$186.09K +35.3%—1.5%
PMNProMIS Neurosciences, Inc.Jun 2026-$371.18K +0.0%—0.7%
MPLTMapLight Therapeutics, Inc.Mar 2026-$883K -1138.8%—0.2%
ANLAdlai Nortye Ltd.Dec 2025-$4.35M +4.2%+21.9%12.6%
Peer median (excluding PMN) -$883K+4.2%+21.9%1.5%

Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Cash & Equivalents21.43M10.69M12.6M13.29M6.12M
Short-term Investments50.69K79.89K32.36K33.05K33.75K
Net Receivables0078.64K78.03K36.52K
Inventory00000
Other Current Assets768.78K768.19K228.85K47.28K70.48K
Total Current Assets22.4M12.56M13.62M18.91M9.18M
Property, Plant & Equipment (Net)5.91K584000
Goodwill00000
Intangible Assets34.92K37.91K000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets40.83K38.49K000
Total Assets22.44M12.6M13.62M18.91M9.18M
Account Payables517.17K5.41M7.84M1.74M2.54M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00518.7K38.33K79.75K
Total Current Liabilities1.17M11.67M9.35M2.22M10.41M
Long-term Debt4.94M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.17M3.38M516.19K204.86K29.18K
Total Non-current Liabilities14.11M3.38M516.19K204.86K29.18K
Total Liabilities15.28M15.05M9.87M2.42M10.44M
Common Stock00000
Retained Earnings(78.64M)(146M)(93.47M)(90.69M)(130.41M)
Accumulated OCI(237.63K)(355.42K)(371.18K)(371.18K)(371.18K)
Other Stockholders Equity0946000
Minority Interest00000
Total Equity7.16M(2.45M)3.75M16.49M(1.26M)
Total Debt4.94M0000
Net Debt(16.49M)(10.69M)(12.6M)(13.29M)(6.12M)

ProMIS Neurosciences, Inc.

NASDAQ:PMN

Intrinsic Alpha fair value

Locked

Current Price

$11.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.